What Can Europe and the U.S. Learn from Each Other on Market Access, Anne Loos?

Tune in to this new episode of MAP, the Market Access Podcast, where Dr. Stefan Walzer is joined by Anne Loos from Wickenstones, to explore the evolving landscape of U.S. market access and reimbursement. The U.S. reimbursement landscape is changing — driven by AI, global influences with the European JCA and political programs such as the Inflation Reduction Act. As fragmentation and rising complexity are pushing pharma to rethink strategy and timelines - this is a must-listen for professionals in pricing, HEOR, and market access.Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts —and if you enjoyed the episode, don’t forget to rate it and the podcast!MAP is the first and only bi-weekly market access podcast provided by MArS — and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/#MarketAccess #ArtificialIntelligence #Reimbursement #PharmaAI #HealthcareStrategy #HTA #USHealthcare #MAPPodcast #marketaccess #marketaccesspodcast

Join this episode of MAP – The Market Access Podcast as Dr. Stefan Walzer sits down with Anna Forsythe, founder of OncoScope-AI, to explore how Living Systematic Literature Reviews (Living SLRs) are redefining evidence generation in oncology and beyond - highlighting the power of real-time updates, advanced automation, and the essential role of human insight.Traditional SLRs are static snapshots, while Living SLRs are real-time, dynamic, and AI-powered—delivering continuously updated insights crucial for life-or-death decisions and payer evaluations. Join this discussion as they explore the myth of AI chatbots as true decision support tools, the need for actionable data over summaries, and the future of evidence synthesis, clinical decision-making, and smarter market access.Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/#MarketAccess #HealthEconomics #AIinHealthcare #SLR #Oncology #HTA #MAPPodcast #marketaccess #marketaccesspodcast

In the latest MAP Podcast, our host Dr. Stefan Walzer is joined by Dr. Malina Müller from the WifOR Institute to rethink how we value health. From real-world ROI data to policy shifts and long-term strategies, they explore why investing in health pays off—not just in lives saved, but in economic growth, workforce productivity, and resilient societies.Listen now to discover how viewing healthcare as an investment—not just a cost—can transform market access and what it means for pricing, innovation, and the future of care. If you work in pharma, policy, or health economics—this one’s for you!Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/#MarketAccess #HealthEconomics #ValueBasedHealthcare #HealthInvestment #Pharma #HTA #MAPPodcast #marketaccess #marketaccesspodcast

In this episode of MAP - the Market Access Podcast, Dr. Stefan Walzer sits down with expert Prof. Dr. Thomas Hammerschmidt, to dive deep into Germany’s evolving AMNOG framework and what it really means for pharmaceutical pricing. This insightful conversation explores key changes in Germany’s pharma landscape, including the shift from negotiation-based pricing to benefit-linked guardrails, the 5% clinical trial rule, and their impact on innovation and reimbursement strategy. A must-listen for pharma professionals, health economists, and market access leaders!Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/#MarketAccess #HealthEconomics #PharmaPricing #AMNOG #Reimbursement #Germany #HTA #PharmaStrategy #marketaccess #marketaccesspodcast

Tune in to this episode of MAP – The Market Access Podcast, to hear from Dr. Stefan Walzer as he speaks with Swiss reimbursement expert Petra Erni, who brings a rare perspective from both the industry and payer sides.Together they explore the evolving Swiss drug reimbursement landscape, discussing the rise of cost consequence models, the growing role of health economic evidence, early access pathways, and strategic pricing challenges in Switzerland. Essential listening for pharma, market access, and health policy professionals—especially those eyeing the Swiss market.Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/#MarketAccess #PharmaPricing #Switzerland #HealthEconomics #Reimbursement #HTA #DrugPricing #HealthcareStrategy #marketaccess #marketaccesspodcast

This is a repost of a popular episode of MAP - Market Access Podcast, from December 1st 2023.We are thrilled to announce our latest podcast episode, featuring a riveting conversation between our CEO Dr. Stefan Walzer and the esteemed healthcare reimbursement expert, Ron de Graaff. Ron, with his deep-rooted experience starting from 1978, shares his invaluable insights on the evolution of healthcare reimbursement, a journey from simpler times to today's intricate landscape involving multiple stakeholders like health insurance companies.🔍 Key Highlights:- Ron's path from founding his company in 1985, which has since assisted over 900 entities, including governments, in understanding medical technology markets.- Challenges faced by startups in healthcare, often led by technical experts who struggle with the language and complexities of reimbursement processes.- The criticality of startups understanding both the payer perspectives and the changing requirements of reimbursement systems across Europe.- Ron's advice to startups: comprehensively understand the reimbursement system of your target market and assess if your product is likely to be reimbursable.This episode is a must-listen for anyone in the healthcare industry, particularly startups navigating the daunting world of reimbursement. Expect to gain a thorough understanding of how to strategically plan for reimbursement, the importance of being updated with current regulations, and how to choose the right market for your product.Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/#MarketAccess #HealthcareReimbursement #StartupChallenges #MedicalTechnology #Podcast #HealthcareInnovation #marketaccess #marketaccesspodcast

In this thought-provoking episode of MAP, the Market Access Podcast, Dr. Stefan Walzer sits down with strategic Market Access consultant Dr. Doug Niven to explore one of the most pressing questions in pharma today - can Europe maintain its leadership in Market Access, or is it falling behind? From joint HTA (JCA), pricing reforms, and AI-driven tools to global value frameworks and real-world data, this episode unpacks key trends shaping pharma, biotech, and healthcare access in 2025 and beyond. If you're in health economics, pricing & reimbursement, or regulatory strategy, this is a must-listen.Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/#MarketAccess #HealthEconomics #PharmaStrategy #PricingAndReimbursement #HTA #marketaccess #marketaccesspodcast

Tune in to this new episode of the Market Access Podcast, where our host Dr. Stefan Walzer is joined by AMNOG expert Anja Pownell to bust some of the most persistent misconceptions about German market access—and share actionable survival tips for navigating the GBA process.Learn how to strategically prepare for AMNOG submissions, navigate price negotiations, and leverage AI tools to streamline dossier writing and literature reviews. A must-listen for anyone involved in pharmaceutical pricing, reimbursement, and European market access strategy.Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/#MarketAccess #HealthEconomics #HealthcareInnovation #PharmaStrategy #AMNOG #PharmaInnovation  #GBA #Reimbursement #marketaccess #marketaccesspodcast

In this episode of the Market Access Podcast, Dr. Stefan Walzer sits down with Kasem Akhras, veteran access strategist and author of Frontiers in Market Access, to unpack what it really takes to bring innovative therapies to patients across emerging markets. From the rising demand for innovative therapies to the tightening grip of healthcare budgets, this episode explores the real challenges and opportunities in market access today. Discover why pricing strategies must be tailored to each market, how cross-functional collaboration and early planning are key to success, and how digital health and AI are reshaping the future of market access. A must-listen for anyone navigating the complexities of global market access.Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/#MarketAccess #HealthEconomics #EmergingMarkets #PricingStrategy #PharmaInnovation #DigitalHealth #AIinPharma #marketaccess #marketaccesspodcast

Tune in to the latest episode of the Market Access Podcast, where Dr. Stefan Walzer welcomes statistician and Evimed founder Necdet Gunsoy to explore the critical role of statistics in health economics, HTA, and payer strategy. Learn how better collaboration between statisticians and market access teams can drive evidence-based decision-making, improve communication, and support strategic planning—plus the impact of AI on future workflows.This conversation spans key topics—from real-world evidence and health technology assessment (HTA) to internal cross-functional alignment and strategic planning in market access. Whether you're a health economist, market access leader, or data expert, this is a must-listen to improve cross-functional impact and efficiency.Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/#MarketAccess #HealthEconomics #HTA #Pharma #PayerStrategy #marketaccess #marketaccesspodcast